CleanSpark Inc vs Eli Lilly And Co — how do they compare? CleanSpark Inc trades at $13.54 (market cap $3.45B), while Eli Lilly And Co trades at $1,150.88 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 298.6× CleanSpark Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| CLSK | LLY | |
|---|---|---|
Market Cap | $3.45B | $1.03T |
Sector | Technology | Health |
52-Week High | $23.20 | $1.24K |
52-Week Low | $8.18 | $625.65 |
Enterprise Value | $4.31B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
CleanSpark (CLSK) trades at $12.36, down 3.81% today, with a bearish technical signal and recent earnings misses. The company reported a net loss margin of -67.66% for 2026 but announced a transformative $6.6 billion 20-year AI data center lease, shifting focus from Bitcoin mining to high-performance computing. Analyst consensus remains unanimously bullish with a $21.43 price target, highlighting growth potential despite current profitability challenges.
The outlook balances high growth potential from the AI pivot against significant execution risks and persistent losses. Near-term volatility is expected as the market assesses the company's ability to monetize new contracts and achieve sustainable profitability. The stock presents a high-risk, high-reward opportunity dependent on successful business model transition.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →